Low CD34+cell count and metabolic syndrome synergistically increase the risk of adverse outcomes
Low CD34+cell count and metabolic syndrome synergistically increase the risk of adverse outcomes
复制标题
DOI：
10.1016/j.atherosclerosis.2009.03.040
复制
发表时间：
2009-11-01
期刊：
影响因子：
5.3
通讯作者：
Avogaro, Angelo
中科院分区：
文献类型：
--
作者：
Fadini, Gian Paolo;de Kreutzenberg, Saula;Avogaro, Angelo
目的：代谢综合征（MetS）与内皮功能障碍、心血管事件和死亡的高风险相关。循环祖细胞已被证明有助于内皮稳态和修复。我们的目的是测试祖细胞计数是否是一个独立的事件预测因子，并修改与MetS.Methods心血管疾病的风险：CD34，CD133和KDR的表达的基础上，6个表型的祖细胞使用流式细胞术计数在214例受试者与非MetS。我们记录了经典的危险因素和代谢综合征的组成部分，累积风险估计，和高敏C反应蛋白。受试者随访中位数为34个月，收集总事件，心血管事件和全因mortals.Results：在考克斯比例风险回归分析，我们发现，与其他表型，减少CD34+细胞预测心血管和总事件和死亡，独立于所有潜在的混杂因素。值得注意的是，低的CD34+细胞计数显着增加与代谢综合征的风险，如协同indexs.Conclusion：循环CD34+细胞的水平是一种新的独立的风险生物标志物，并调制的结果在代谢综合征，这表明，通用祖细胞在疾病的发展或进展的长期的作用。(C)2009爱思唯尔爱尔兰有限公司保留所有权利。
Objectives: Metabolic syndrome (MetS) associates with endothelial dysfunction and a high risk of cardiovascular events and death. Circulating progenitor cells have been shown to contribute to endothelial homeostasis and repair. We aimed to test whether progenitor cell count is an independent event predictor and modifies cardiovascular risk associated with MetS.Methods: On the basis of the expression of CD34, CD133 and KDR, 6 phenotypes of progenitor cells were counted using flow cytometry in 214 subjects with and without MetS. We recorded classical risk factors and MetS components, cumulative risk estimates, and high-sensitive C-reactive protein. Subjects were followed-up for a median of 34 months to collect total events, cardiovascular events and all-cause mortality.Results: In the Cox proportional hazards regression analyses, we found that, unlike other phenotypes, reduced CD34+ cells predicted cardiovascular and total events and death, independently of all potential confounders. Remarkably, a low CD34+ cell count significantly increased the risk associated with MetS, as shown by synergy indexes.Conclusion: The level of circulating CD34+ cells is a novel independent risk biomarker and modulates outcomes in the MetS, suggesting that generic progenitor cells have a role in disease development or progression over the long-term. (C) 2009 Elsevier Ireland Ltd. All rights reserved.